0000899243-20-008004.txt : 20200311
0000899243-20-008004.hdr.sgml : 20200311
20200311203123
ACCESSION NUMBER: 0000899243-20-008004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200310
FILED AS OF DATE: 20200311
DATE AS OF CHANGE: 20200311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HAUSMAN DIANA
CENTRAL INDEX KEY: 0001563992
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38068
FILM NUMBER: 20706946
MAIL ADDRESS:
STREET 1: C/O ONCOTHYREON INC.
STREET 2: 2601 FOURTH AVE, SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER NAME:
FORMER CONFORMED NAME: HAUSMAN DIANE
DATE OF NAME CHANGE: 20121207
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zymeworks Inc.
CENTRAL INDEX KEY: 0001403752
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 540-1385 WEST 8TH AVENUE
CITY: Vancouver
STATE: A1
ZIP: V6H 3V9
BUSINESS PHONE: (604) 678-1388
MAIL ADDRESS:
STREET 1: 540-1385 WEST 8TH AVENUE
CITY: Vancouver
STATE: A1
ZIP: V6H 3V9
FORMER COMPANY:
FORMER CONFORMED NAME: Zymeworks Inc
DATE OF NAME CHANGE: 20070620
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-10
0
0001403752
Zymeworks Inc.
ZYME
0001563992
HAUSMAN DIANA
C/O ZYMEWORKS INC.
1385 WEST 8TH AVENUE, SUITE 540
VANCOUVER
A1
V6H 3V9
BRITISH COLUMBIA, CANADA
0
1
0
0
Chief Medical Officer
Stock Option (Right to Buy)
35.20
2020-03-10
4
A
0
45000
0.00
A
2030-03-09
Common Shares
45000
45000
D
Restricted Stock Unit
2020-03-10
4
A
0
7500
0.00
A
Common Shares
7500
7500
D
Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The restricted stock units vest in three equal annual installments beginning on March 10, 2021.
/s/ Daniel Dex, Attorney-in-Fact
2020-03-11